Results 51 to 60 of about 1,302,201 (345)
EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines
Molecular Oncology, EarlyView.The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche +8 more
wiley +1 more source
Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors
Cells, 2022 The mutation-driven transformation of clinical anti-androgen drugs into agonists of the human androgen receptor (AR) represents a major challenge for the treatment of prostate cancer patients. To address this challenge, we have developed a novel class of
Mariia Radaeva +12 more
doaj +1 more source
Molecular Oncology, EarlyView.Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva +5 more
wiley +1 more source
Molecular Oncology, EarlyView.Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon +13 more
wiley +1 more source
Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer
New England Journal of Medicine, 2018 BACKGROUND Men with nonmetastatic, castration‐resistant prostate cancer and a rapidly rising prostate‐specific antigen (PSA) level are at high risk for metastasis.
M. Hussain +11 more
semanticscholar +1 more source
ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma
Molecular Oncology, EarlyView.In SMAD4‐positive pancreatic ductal adenocarcinoma (PDAC), integrin subunit alpha V (ITGAV) activates latent TGF‐β, which binds to the TGF‐β receptor and phosphorylates SMAD2/3. The activated SMAD2/3 forms a complex with SMAD4, and together they translocate to the nucleus, modulating gene expression to promote proliferation, migration, and invasion. In
Daniel K. C. Lee +9 more
wiley +1 more source
Prostate International, 2015 Purpose: To determine the incidence and clinical features of incidentally discovered prostate adenocarcinoma in patients undergoing radical cystoprostatectomy (CPT) for bladder cancer.
In-Chang Cho +7 more
doaj +1 more source
Xanthogranulomatous Prostatitis, a Rare Prostatic Entity
Urology Case Reports, 2017 There are several benign prostatic pathologies that can clinically mimic a prostate adenocarcinoma. Xanthogranulomatous prostatitis is a benign inflammatory condition of the prostate and a rare entity. A 47-year old male, with 3 years of lower urinary tract symptoms, with a palpable hypogastric tumor, digital rectal examination: solid prostate, of ...
Omar Piñon +8 more
openaire +3 more sources
Molecular Oncology, EarlyView.This study presents a novel AI‐based diagnostic approach—comprehensive serum glycopeptide spectra analysis (CSGSA)—that integrates tumor markers and enriched glycopeptides from serum. Using a neural network model, this method accurately distinguishes liver and pancreatic cancers from healthy individuals.
Motoyuki Kohjima +6 more
wiley +1 more source
Using real world data to bridge the evidence gap left by prostate cancer screening trials
ESMO Real World Data and Digital OncologyBackground and purpose: Population-based prostate cancer screening is currently not recommended in the UK because harms may outweigh benefits. Recent changes to the diagnostic pathway have improved safety and accuracy, but uncertainty remains as to how ...
N. Norori +7 more
doaj +1 more source